Adalimumab
Active ingredient description
Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Medicines
Adalimumab is the active ingredient of these drugs:
Australia Austria Brazil Cyprus Ecuador
Austria Estonia Ireland Lithuania Poland
Estonia Lithuania
Australia
Austria Estonia Lithuania Poland
Austria Estonia Ireland Lithuania Poland
Estonia Ireland Poland Romania
Austria Ecuador Estonia Finland France
Australia Austria Brazil Canada Cyprus
Australia Austria Brazil Cyprus Ecuador
Australia Austria Brazil Cyprus Ecuador
Austria Cyprus Estonia Finland France
Estonia Lithuania Poland
Estonia Ireland Poland
Ecuador
Estonia Lithuania
Brazil
Estonia Finland Germany Ireland Lithuania